![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tVtnMtZtop2eaTBpfRjdoe_emvJYrxPCJtVTUCIPtsik_DefGA3YiFBumOBHEbQ8hAWmcfluuF87yACwTXhHEW5ehSxAwJHFujAYfrVUk=s0-d){kind=small}
Public release date: 13-Dec-2012[ | E-mail |
Share ] Contact: Raquel Maurier
raquel.maurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry
Researchers find Achilles heel of some cancers
Medical researchers at the University of Alberta have discovered that knocking out a particular "partner" gene is the Achilles' heel of some cancers.
Cancer causing genes often have a partner in crime, meaning when either of the two genes is active in cancer cells, the tumour grows. The challenge for researchers has been pinpointing the genes lethal partners. Loss of one of the partners alone isnt deadly to the cell, but if both are gotten rid of, the cancer cells are destroyed.
Faculty of Medicine & Dentistry researcher Michael Weinfeld and his collaborators, Edan Foley and graduate student Todd Mereniuk, took cells and artificially removed a particular gene known as PKNP. Then the team knocked out 7,000 other genes, one at a time, all in an effort to find PKNP's "lethal partners" that trigger cell death.
And the team found ita deadly partner gene, a rare type of cancer suppressor typically missing in lymphomas.
The team confirmed their findings by examining tumours that lacked this specific cancer suppressor. They then inactivated PKNP, which caused the cancer cells to die. Their findings were published in the peer-reviewed journal Cancer Research.
Developing cancer drugs that inactivate PKNP will result in only the cancer cells that lack this gene being eradicated, not healthy, normal cells, says Weinfield, who works in the Department of Oncology at the U of A.
"Lots of work in the cancer research field is to try and come up with ways to attack cancer cells and leave normal cells intact," he says. "You need to take advantage of whatever you can to defeat cancer, which can be extremely difficult."
Weinfeld and his colleagues are now working with Dennis Hall in the Department of Chemistry at the U of A and the Centre for Drug Research and Development in British Columbia to improve this potential drug they've discovered. They are also partnering with John Lewis, the Frank and Carla Sojonky Chair in Prostate Cancer Research in the Faculty of Medicine & Dentistry, to work with his cancer-targeting nanotechnology theories.
###
The team's research was funded by a grant from the Canadian Institutes of Health Research.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 13-Dec-2012[ | E-mail |
Share ] Contact: Raquel Maurier
raquel.maurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry
Researchers find Achilles heel of some cancers
Medical researchers at the University of Alberta have discovered that knocking out a particular "partner" gene is the Achilles' heel of some cancers.
Cancer causing genes often have a partner in crime, meaning when either of the two genes is active in cancer cells, the tumour grows. The challenge for researchers has been pinpointing the genes lethal partners. Loss of one of the partners alone isnt deadly to the cell, but if both are gotten rid of, the cancer cells are destroyed.
Faculty of Medicine & Dentistry researcher Michael Weinfeld and his collaborators, Edan Foley and graduate student Todd Mereniuk, took cells and artificially removed a particular gene known as PKNP. Then the team knocked out 7,000 other genes, one at a time, all in an effort to find PKNP's "lethal partners" that trigger cell death.
And the team found ita deadly partner gene, a rare type of cancer suppressor typically missing in lymphomas.
The team confirmed their findings by examining tumours that lacked this specific cancer suppressor. They then inactivated PKNP, which caused the cancer cells to die. Their findings were published in the peer-reviewed journal Cancer Research.
Developing cancer drugs that inactivate PKNP will result in only the cancer cells that lack this gene being eradicated, not healthy, normal cells, says Weinfield, who works in the Department of Oncology at the U of A.
"Lots of work in the cancer research field is to try and come up with ways to attack cancer cells and leave normal cells intact," he says. "You need to take advantage of whatever you can to defeat cancer, which can be extremely difficult."
Weinfeld and his colleagues are now working with Dennis Hall in the Department of Chemistry at the U of A and the Centre for Drug Research and Development in British Columbia to improve this potential drug they've discovered. They are also partnering with John Lewis, the Frank and Carla Sojonky Chair in Prostate Cancer Research in the Faculty of Medicine & Dentistry, to work with his cancer-targeting nanotechnology theories.
###
The team's research was funded by a grant from the Canadian Institutes of Health Research.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-12/uoaf-umr_1121012.php
Ronda Rousey BCS Bowls palestine powerball winner powerball winner steelers jessica simpson
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন